Cyclic Peptides Patents (Class 530/317)
-
Patent number: 8258258Abstract: Disclosed is a polypeptide comprising at least two microproteins, which preferably comprise an amino acid sequence having a specific binding activity to a target protein. Furthermore, disclosed are polynucleotides encoding such a polypeptide as well as pharmaceutical compositions and kits comprising said polypeptide or polynucleotide. Also disclosed herein are methods of treatments and second medical uses applying the disclosed polypeptide or polynucleotide. Additionally, the disclosure of the present application relates to a method for forming a covalent bond in a microprotein which can be used for producing the disclosed polypeptides.Type: GrantFiled: March 9, 2006Date of Patent: September 4, 2012Assignee: BioNTech AGInventors: Harald Kolmar, Ernst Boehnlein, Alexander Wentzel, Hans-Ulrich Schmoldt
-
Patent number: 8258101Abstract: This invention relates to new peptide-based compounds and their use in therapeutically effective treatments as well as for diagnostic imaging techniques. More specifically the invention relates to the use of such peptide-based compounds used as targeting vectors that bind to receptors associated with angiogenesis, in particular the ?v?3 integrin receptor. Such contrast agents may thus be used for diagnosis of for example malignant diseases, heart diseases, inflammation-related diseases, rheumatoid arthritis and Kaposi's sarcoma. Moreover such compounds may also be used in therapeutic treatment of these diseases.Type: GrantFiled: June 14, 2010Date of Patent: September 4, 2012Assignee: GE Healthcare ASInventor: Alan Cuthbertson
-
Publication number: 20120219498Abstract: An isolated peptide comprising an amino acid sequence HWRR as set forth by SEQ ID NO:5, the peptide consists of 4 or 5 amino acids, is provided. Also provided are methods of treating angiogenesis-related pathologies using the peptide of the invention or pharmaceutical compositions comprising same.Type: ApplicationFiled: May 10, 2012Publication date: August 30, 2012Applicant: RAMOT AT TEL-AVIV UNIVERSITY LTD.Inventors: BRITTA HARDY, ALEXANDER RATTLER, ANNAT RAITER, CHANA WEISS
-
Publication number: 20120220535Abstract: A composition which is reversible inhibitor of at least one neuron-specific PDZ domain comprising wherein R is a molecular transporter with or without a linker amino acid; R1 is at least about one amino acid covalently bound; and, R2 is isoleucine, leucine, alanine, phenylalanine, or valine, and methods of use.Type: ApplicationFiled: May 18, 2010Publication date: August 30, 2012Inventors: Mark Spaller, John Marshall, Dennis J. Goebel
-
Publication number: 20120220752Abstract: A free amino acid and/or amino ion-releasing molecule useful for a wide variety of medical and cosmetic applications. The chemical name of the new molecule nino-gl ino-parabenzoate, sometimes referred to herein as TAFA.Type: ApplicationFiled: October 31, 2011Publication date: August 30, 2012Inventor: STEVEN R. SCHUTT
-
Publication number: 20120220539Abstract: The present invention relates conotoxin peptides that are analogs of the ?-contoxin peptide RgIA. These conotoxin peptides block the ?9?10 subtype of the nicotinic acetylcholine receptor (nAChR) and can be used for treating pain, such as neuropathic pain and inflammatory pain, inflammatory disorders, such as rheumatic diseases, and in the treatment of breast cancer.Type: ApplicationFiled: November 4, 2011Publication date: August 30, 2012Applicant: UNIVERSITY OF UTAH RESEARCH FOUNDATIONInventors: J. Michael MCINTOSH, Baldomero M. OLIVERA, Michael ELLISON, Michelle A. VINCLER
-
Patent number: 8252908Abstract: Disclosed are monoclonal antibodies, binding fragments, and derivatives thereof directed to the human melanocortin-4 receptor, as well as pharmaceutical compositions including the same, and therapeutic uses, including methods for treating cachexia and related conditions and diseases, using such monoclonal antibodies, binding fragments, derivatives, and pharmaceutical compositions.Type: GrantFiled: December 30, 2008Date of Patent: August 28, 2012Assignee: Universitaet BaselInventors: Karl Hofbauer, Jean-Christophe Peter
-
Patent number: 8252895Abstract: The present invention relates to a new cyclic peptide compound or a salt thereof, which has anti-hepatitis C virus activities based on inhibitory activity against the RNA replication of hepatitis C virus replicon, to a process for preparation thereof comprising a rearrangement reaction under a mild acidic condition and the following amino acid changing reactions etc., to a pharmaceutical composition comprising the same, and to a method for prophylactic and/or therapeutic treatment of hepatitis C in a human being or an animal.Type: GrantFiled: July 21, 2010Date of Patent: August 28, 2012Assignee: Astellas Pharma Inc.Inventors: Masahiro Neya, Seiji Yoshimura, Kazunori Kamijyo, Takuya Makino, Minoru Yasuda, Toshio Yamanaka, Eisaku Tsujii, Yukiko Yamagishi
-
Publication number: 20120214967Abstract: This invention provides cross-linked glycopeptide-cephalosporin compounds and pharmaceutically acceptable salts thereof which are useful as antibiotics. This invention also provides pharmaceutical compositions containing such compounds; methods for treating bacterial infections in a mammal using such compounds; and processes and intermediates useful for preparing such compounds.Type: ApplicationFiled: September 21, 2011Publication date: August 23, 2012Applicant: THERAVANCE, INC.Inventor: Daniel D. Long
-
Patent number: 8247372Abstract: Compounds which are Spiruchostatin analogues of the general formula (I) or (I?), isosteres thereof and pharmaceutically acceptable salts thereof are found to inhibit HDAC wherein R1, R2, R3 and R4 are the same or different and represent an amino acid side chain moiety and each R6 is the same or different and represents hydrogen or C1-C4 alkyl.Type: GrantFiled: November 23, 2007Date of Patent: August 21, 2012Assignee: University of SouthamptonInventors: Graham Keith Packham, Arasu Ganesan, Alexander Richard Liam Cecil
-
Publication number: 20120208981Abstract: The present invention concerns a method of purifying colistin using reverse phase chromatography, wherein loading a column with colistin base in acetic acid and high ethanol concentration and eluting with low ethanol concentration is performed.Type: ApplicationFiled: September 29, 2010Publication date: August 16, 2012Applicant: XELLIA PHARMACEUTICALS APSInventors: Torben Koch, Carsten Overblle Petersen
-
Patent number: 8242250Abstract: The present invention relates to a novel nucleic acid molecule encoding an amino acid sequence, which is capable of forming a cyclic structure. Cyclization may occur within a cell or cell membrane, or linear forms of the molecules may be circularised or partially circularised, in vitro using isolated enzyme systems or chemical means. The cyclised amino acid sequence is generally in the form of a stabilized folded structure such as acyclic knotted peptide, polypeptide or protein or functional equivalent. The nucleic acid molecules and cyclic and linear peptides are useful inter alia in the generation of molecules having animal or plant therapeutic properties, as well as in a range of diagnostic, industrial and agricultural, including horticultural, applications. Of particular importance is the use of these molecules in the protection of plants, such as crop plants, from pest and/or pathogen infestation.Type: GrantFiled: August 26, 2009Date of Patent: August 14, 2012Assignees: The University of Queensland, Hexima LimitedInventors: David James Craik, Marilyn Anne Anderson, Cameron Victor Jennings
-
Publication number: 20120202733Abstract: Peptides are provided consisting of L- and/or D-amino acids and combinations thereof, which affect myeloid cells by action on the triggering receptors expressed on myeloid cells (TREMs), including TREM-1 and TREM-2. The peptides act on the TREM/DAP-12 signaling complex. Also provided are lipid and sugar conjugated peptides comprising L- or D-amino acids. A method is provided of designing the peptides and lipid- and/or sugar-conjugated peptides comprising L- or D-amino acids. The disclosure relates to the therapy of various myeloid cell-related disease states involving the use of these peptides and compounds. The peptides and compounds are useful in the treatment and/or prevention of a disease or condition where myeloid cells are involved or recruited. The peptides of the present invention also are useful in the production of medical devices comprising peptide matrices (for example, medical implants and implantable devices).Type: ApplicationFiled: October 13, 2010Publication date: August 9, 2012Applicant: SIGNABLOK, INC.Inventor: Alexander B. Sigalov
-
Publication number: 20120202968Abstract: The present invention concerns 2-amino-3-methyl-hex-5-enoic acid, its use for the production of peptides such as bacitracins and a method for producing it.Type: ApplicationFiled: September 30, 2010Publication date: August 9, 2012Applicant: XELLIA PHARMACEUTICALS APSInventors: Martin Mansson, Christine Senstad, Jon Efskind, Vidar Bjornstad
-
Publication number: 20120196792Abstract: The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.Type: ApplicationFiled: April 4, 2012Publication date: August 2, 2012Applicants: ENANTA PHARMACEUTICALS, INC., ABBOTT LABORATORIESInventors: Yiyin Ku, Keith F. McDaniel, Hui-Ju Chen, Jason P. Shanley, Dale J. Kempf, David J. Grampovnik, Ying Sun, Dong Liu, Yonghua Gai, Yat Sun Or, Seble H. Wagaw, Ken Engstrom, Tim Grieme, Ahmad Sheikh, Jianzhang Mei
-
Publication number: 20120196790Abstract: The present application relates to cyclic depsipeptides, or derivatives thereof, having the structure of formula (I), and uses thereof, e.g. as inhibitors of kallikrein 7 and human neutrophil elastase.Type: ApplicationFiled: February 14, 2012Publication date: August 2, 2012Applicant: NOVARTIS AGInventors: Philipp KRASTEL, Brigitta-Maria LIECHTY, Josef Gottfried MEINGASSNER, Esther SCHMITT, Erwin Paul SCHREINER
-
Publication number: 20120190815Abstract: The present invention disclosed a novel azacyclohexapeptide or pharmaceutically acceptable salts, preparation methods and uses thereof.Type: ApplicationFiled: August 6, 2009Publication date: July 26, 2012Inventors: Tianhui Xu, Tao Fang, Zhonghao Zhuo, Yunman Zheng, Xiaoming Ji
-
Publication number: 20120190613Abstract: The invention features echinocandin class compounds that have been modified to (i) have activity against one or more fungal species or genera; (ii) have increased aqueous solubility; (iii) have an increased therapeutic index; (iv) be suitable for topical administration; and/or (v) be suitable for oral administration. The echinocandin class compounds of the invention include, for example, a PEG, alkyl-PEG, aryl-PEG, alkaryl-PEG, PEG-alkyl, PEG-aryl, or PEG-alkaryl substituent.Type: ApplicationFiled: August 26, 2010Publication date: July 26, 2012Inventors: Kenneth Duke James, JR., Christopher Patrick Laudeman
-
Patent number: 8227422Abstract: Described are peptides and peptide mimetics that bind to and activate the thrombopoietin receptor. Such peptides and peptide mimetics are useful in methods for treating hematological disorders and particularly, thrombocytopenia resulting from chemotherapy, radiation therapy, or bone marrow transfusions as well as in diagnostic methods employing labeled peptides and peptide mimetics.Type: GrantFiled: December 13, 2006Date of Patent: July 24, 2012Assignee: Glaxosmithkline LLCInventors: William J. Dower, Ronald W. Barrett, Steven E. Cwirla, David J. Duffin, Christian M. Gates, Sherril S. Haselden, Larry C. Mattheakis, Peter J. Schatz, Christopher R. Wagstrom, Nicholas C. Wrighton
-
Publication number: 20120178900Abstract: The present disclosure demonstrates the utility of ion pairing agents in the preparative scale of purification. More particularly, the disclosure relates to the usage of ion pairing agents in RP preparative linear chromatography enabling high purity of the desired end product. The disclosure shows that ion-pairing agents have dramatic effect on desired purity of polypeptides.Type: ApplicationFiled: August 9, 2010Publication date: July 12, 2012Applicant: BIOCON LIMITEDInventors: Nitesh Dave, Krishana Chaitanya Gulla, Sundaresh Shankar, Harish Iyer
-
Publication number: 20120178694Abstract: Compounds comprising peptides capable of binding C3 protein and inhibiting complement activation are disclosed. These compounds display greatly improved complement activation-inhibitory activity as compared with currently available compounds. The compounds comprise compstatin analogs having a constrained backbone at position 8 (glycine) and, optionally, specific substitutions for threonine at position 13.Type: ApplicationFiled: May 3, 2010Publication date: July 12, 2012Inventors: John D. Lambris, Hongchang Qu
-
Publication number: 20120178701Abstract: Melanocortin receptor-specific cyclic peptides of the formula where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and z are as defined in the specification, compositions and formulations including the peptides of the foregoing formula, and methods of preventing, ameliorating or treating melanocortin receptor-mediated diseases, indications, conditions and syndromes.Type: ApplicationFiled: December 6, 2011Publication date: July 12, 2012Applicant: PALATIN TECHNOLOGIES, INC.Inventors: Yi-qun Shi, Shubh D. Sharma, John H. Dodd, Wei Yang, Xin Chen
-
Publication number: 20120172315Abstract: The invention relates to the A1 peptide of the sequence RRKYGRDFLLRF, as well as to certain variants thereof, for treating cancers, in particular malignant hematopoietic diseases, and more particularly for treating chronic lymphoid leukaemia.Type: ApplicationFiled: March 5, 2010Publication date: July 5, 2012Inventors: Bertrand Cosson, Hussam Saad, Patrick Cormier, Christian Berthou, Mirjam Czjzek
-
Patent number: 8211855Abstract: A composition is disclosed herein comprising from about 0.001% to about 0.Type: GrantFiled: September 18, 2007Date of Patent: July 3, 2012Assignee: Allergan, Inc.Inventors: James N. Chang, Orest Olejnik, Bruce A. Firestone
-
Compositions and Methods for Treatment of Thrombosis and for Prolonging Survival of Stored Platelets
Publication number: 20120165258Abstract: Provided herein are methods and compositions, including pharmaceutical compositions, for treating thrombosis, vascular inflammation, and thrombocytopenia. The methods and compositions of the present invention are also useful for extending the useful storage shelf life of platelets.Type: ApplicationFiled: June 24, 2011Publication date: June 28, 2012Applicant: VASCULOGICS, INC.Inventor: Gray D. Shaw -
Publication number: 20120165228Abstract: Nature evolves biological molecules such as proteins through iterated rounds of diversification, selection, and amplification. The present invention provides methods, compositions, and systems for synthesizing, selecting, amplifying, and evolving non-natural molecules based on nucleic acid templates. The sequence of a nucleic acid template is used to direct the synthesis of non-natural molecules such as unnatural polymers and small molecules. Using this method combinatorial libraries of these molecules can be prepared and screened. Upon selection of a molecule, its encoding nucleic acid template may be amplified and/or evolved to yield the same molecule or related molecules for re-screening. The inventive methods and compositions of the present invention allow for the amplification and evolution of non-natural molecules in a manner analogous to the amplification of natural biopolymer such as polynucleotides and protein.Type: ApplicationFiled: June 30, 2011Publication date: June 28, 2012Inventors: David R. Liu, Zev Gartner, Matthew W. Kanan
-
Patent number: 8198403Abstract: The present invention includes compositions and methods for the isolation, separation and chelation of Carbon Nanotubes (CNTs) using a cyclizable peptide.Type: GrantFiled: May 26, 2006Date of Patent: June 12, 2012Assignee: Board of Regents, The University of Texas SystemInventors: Gregg R. Dieckmann, Alfonzo Ortiz-Acevedo, Ray Baughman, Alan B. Dalton, Rockford K. Draper, Inga H. Musselman
-
Patent number: 8198405Abstract: Novel polypeptides and methods of making and using the same are described herein. The polypeptides include cross-linking (“hydrocarbon stapling”) moieties to provide a tether between two amino acid moieties, which constrains the secondary structure of the polypeptide. The polypeptides described herein can be used to treat diseases characterized by excessive or inadequate cellular death.Type: GrantFiled: July 30, 2008Date of Patent: June 12, 2012Assignees: Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard CollegeInventors: Loren D. Walensky, Stanley J. Korsmeyer, Susan Korsmeyer, legal representative, Gregory Verdine
-
Publication number: 20120142892Abstract: According to the present invention, there is provided a range of new conotoxin derivatives and methods for synthesizing these analogues and other intramolecular dicarba bridge-containing peptides, including dicarba-disulfide bridge-containing peptides.Type: ApplicationFiled: February 16, 2012Publication date: June 7, 2012Applicants: POLYCHIP PHARMACEUTICALS PTY LTD., MONASH UNIVERSITYInventors: Andrea Robinson, Jomana Elaridi
-
Patent number: 8193310Abstract: Disclosed are short chain peptides that are constrained to adopt an alpha helical conformation and their use as alpha helical scaffolds for directing amino acid side chains into positions analogous to those found in longer chain alpha helical peptides. Also disclosed is the use of these peptides for attaching peptidic or non-peptidic appendages in order to mimic side chains of longer alpha helical peptides. The peptides find use in mimicking naturally occurring peptides or proteins or in preparing new materials.Type: GrantFiled: March 21, 2005Date of Patent: June 5, 2012Assignee: The University of QueenslandInventors: David P. Fairlie, Nicholas E. Shepherd
-
Patent number: 8193312Abstract: A cyclized peptide designated BMP Binding Peptide (BBP) is a synthetic peptide that avidly binds rhBMP-2, as do endogenous forms of BBP, and sequence conservation between species results in a variety of useful BBP compositions. BBP increases the over-all osteogenic activity of rhBMP-2, increases the rate at which rhBMP-2 induces bone formation, and BBP induces calcification alone. Compositions and substrates including BBP, and methods of using BBP are useful in therapeutic, diagnostic and clinical applications requiring calcification and osteogenesis.Type: GrantFiled: November 16, 2007Date of Patent: June 5, 2012Assignees: The Regents of the University of California, The United States of America as represented by the Department of Veterans AffairsInventors: Samuel S. Murray, Elsa J. Murray, Jeffrey C. Wang, Keyvan Behnam
-
Publication number: 20120134923Abstract: The present invention provides a novel method of labelling biological targeting molecules (BTMs) of interest with radioiodine. Also provided are novel radioiodinated BTMs prepared using the method, as well as radiopharmaceutical compositions comprising such radioiodinated BTMs. The invention also provides radioiodinated intermediates useful in the method, as well as in vivo imaging methods using.Type: ApplicationFiled: August 20, 2010Publication date: May 31, 2012Inventors: Michelle Avory, William John Trigg
-
Publication number: 20120135942Abstract: ?-Hairpin peptidomimetics of the general formula Cyclo(-Xaa1-Xaa2-Xaa3-Cys4-Xaa5-Xaa6-Xaa7-Xaa8-Arg9-Tyr10-Cys11-Xaa12-Xaa13-Xaa14-Xaa15-Xaa16-), disulfide bond between Cys4 and Cys11, and pharmaceutically acceptable salts thereof, with Xaa1, Xaa2, Xaa3, Xaa5, Xaa6, Xaa7, Xaa8, Xaa12, Xaa13, Xaa14, Xaa15 and Xaa16 being amino acid residues of certain types which are defined in the description and the claims, have CXCR4 antagonizing properties and can be used for preventing HIV infections in healthy individuals or for slowing and halting viral progression in infected patients; or where cancer is mediated or resulting from CXCR4 receptor activity; or where immunological diseases are mediated or resulting from CXCR4 receptor activity; or for treating immunosuppression; or during apheresis collections of peripheral blood stem cells and/or as agents to induce mobilization of stem cells to regulate tissue repair.Type: ApplicationFiled: May 7, 2009Publication date: May 31, 2012Applicant: POLYPHOR AGInventors: Daniel Obrecht, Frank Otto Gombert, Alexander Lederer, Barbara Romagnoli, Christian Bisang
-
Patent number: 8188219Abstract: A cyclized peptide designated BMP Binding Peptide (BBP) is a synthetic peptide that avidly binds rhBMP-2. BBP increases the over-all osteogenic activity of rgBMP-2, increases the rate at which rhBMP-2 induces bone formation, and BBP induces calcification alone. Compositions and substrates including BBP, and methods of using BBP are useful in therapeutic, diagnostic and clinical applications requiring calcification and osteogenesis.Type: GrantFiled: January 28, 2005Date of Patent: May 29, 2012Assignees: The Regents of the University of California, Department of Veterans AffairsInventors: Samuel S. Murray, Keyvan Behnam, Elsa J. Brochmann-Murray
-
Patent number: 8188216Abstract: A library of macrocyclic compounds of the formula (I) where part (A) is a bivalent radical, a —(CH2)y— bivalent radical or a covalent bond; where part (B) is a bivalent radical, a —(CH2)z— bivalent radical, or a covalent bond; where part (C) is a bivalent radical, a —(CH2)t- bivalent radical, or a covalent bond; and where part (T) is a -Y-L-Z- radical wherein Y is CH2 or CO, Z is NH or O and L is a bivalent radical. These compounds are useful for carrying out screening assays or as intermediates for the synthesis of other compounds of pharmaceutical interest. A process for their preparation of these compounds in a combinatorial manner, is also disclosed.Type: GrantFiled: October 7, 2004Date of Patent: May 29, 2012Assignee: Tranzyme Pharma Inc.Inventors: Pierre Deslongchamps, Yves Dory, Gilles Berthiaume, Luc Ouellet, Ruoxi Lan
-
Patent number: 8188037Abstract: Disclosed are microparticles comprising a somatostatin analogue embedded in a biocompatible pharmacologically acceptable polymer matrix for a long acting release and pharmaceutical compositions comprising such microparticles.Type: GrantFiled: June 8, 2010Date of Patent: May 29, 2012Assignee: Novartis AGInventors: Markus Ahlheim, Michael Ausborn, Olivier Lambert, Marc Riemenschnitter
-
Patent number: 8188217Abstract: The present invention relates to methods for forming dicarba bridges in organic compounds. This involves the use of a pair of complementary metathesisable groups on the organic compound, and subjecting the compound to cross-metathesis under microwave radiation conditions. In an alternative, the compounds contain a turn-inducing group between the pair of cross-metathesisable groups to facilitate the cross-metathesis.Type: GrantFiled: February 16, 2007Date of Patent: May 29, 2012Assignees: Monash University, Polychip Pharmaceuticals Pty Ltd.Inventors: Andrea Jane Robinson, William Roy Jackson, Jim Patel, Jomana Elaridi
-
Publication number: 20120128756Abstract: The present disclosure provides peptides and peptide compositions, which facilitate the delivery of an active agent or an active agent carrier wherein the compositions are capable of penetrating the stratum corneum (SC) and/or the cellular membranes of viable cells.Type: ApplicationFiled: October 5, 2011Publication date: May 24, 2012Inventors: Tracy HSU, Samir M. Mitragotri
-
Patent number: 8183202Abstract: A method for the treatment or prophylaxis of a microbial infection of the lower intestine or colon in a subject is described, wherein the method comprises administration to the subject of a type-B lantibiotic, wherein the type-B lantibiotic may include compounds selected from the group consisting of mersacidin, actagardine, plantaricin, planosporicin, ruminococcin, antibiotic 10789, michiganin and haloduracin, and derivatives and variants thereof.Type: GrantFiled: January 21, 2009Date of Patent: May 22, 2012Assignee: Novacta Biosystems LimitedInventors: Sjoerd Nicolaas Wadman, Michael John Dawson, Jesus Cortes Bargallo
-
Patent number: 8183209Abstract: The invention provides a method of treating T-cell mediated diseases and a method of inhibiting the activation of T-cells using certain diketopiperazines. The invention also provides methods of synthesizing diketopiperazines and pharmaceutical compositions comprising certain diketopiperazines. The invention further provides methods of making improved pharmaceutical compositions of proteins and peptides by either increasing or decreasing the content of diketopiperazines in the compositions and the resultant improved pharmaceutical compositions.Type: GrantFiled: September 28, 2011Date of Patent: May 22, 2012Assignee: DMI Biosciences, Inc.Inventors: David Bar-Or, Raphael Bar-Or, Richard Shimonkevitz
-
Patent number: 8183341Abstract: This invention relates to a novel antibiotic compounds, pharmaceutically acceptable salts and derivatives thereof, and to methods for obtaining such compounds.Type: GrantFiled: December 19, 2007Date of Patent: May 22, 2012Assignee: Novartis AGInventors: Matthew J. Lamarche, Jennifer A. Leeds, Phillipp Krastel, Hans-Ulrich Naegeli
-
Publication number: 20120121682Abstract: Various embodiments of the invention relate to a cRGD peptide derivative and an associated manufacturing method, and to an implant having a coating containing a cRGD peptide derivative. One aspect of the invention is the provision of a cRGD peptide derivative having the formula (1): wherein x=0-8, in particular 4-8, and R is a hydrophobic group.Type: ApplicationFiled: November 8, 2011Publication date: May 17, 2012Inventor: Alexander Borck
-
Publication number: 20120121623Abstract: The present invention relates to monomeric and multimeric peptidic compounds which have antipathogenic, in particular antiviral or/and antibacterial activity. In a preferred aspect, the peptide compounds of the invention have an activity in respect of a broad spectrum of viruses, both DNA and RNA viruses, irrespective of whether they possess virus envelope or not. Further, the present invention refers to compositions comprising said peptidic compounds for medical use, i.e. for the treatment or prevention of pathogenic, in particular viral or/and bacterial infections.Type: ApplicationFiled: August 5, 2010Publication date: May 17, 2012Applicant: SPIDERBIOTCH S.r.L.Inventors: Andrea Giuliani, Giovanna Pirri, Lorena Pizzuto, Santo Landolfo, Giorgio Gribaudo, David Lembo, Davide Gibellini
-
Publication number: 20120121543Abstract: The present invention provides, in part, a Paenibacillus sp. isolate, designated Paenibacillus polymyxa JB05-01-1, as well as an anti-microbial agent obtained from the bacterium or cell culture supernatant thereof. Compositions, methods and uses are also provided.Type: ApplicationFiled: November 14, 2011Publication date: May 17, 2012Applicant: Best Environmental Technologies Inc.Inventors: Ronald Teather, John Baah, Karim Naghmouchi, James Gibbs Watson, Djamel Drider
-
Patent number: 8178520Abstract: The present invention relates to macrocyclic compounds of formula (I): wherein W, n, R1, Ra, Rb, R3, R4, M, Z, ring A and ring B are defined herein, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising them, and their use for the treatment or prevention of infection by hepatitis C virus.Type: GrantFiled: May 11, 2007Date of Patent: May 15, 2012Assignee: Istituto di Ricerche di Biologia Molecolare P. Angeletti SpAInventors: Maria Emilia Di Francesco, Emanuela Nizi, Paola Pace, Vincenzo Summa
-
Patent number: 8178650Abstract: The present application relates to cyclic depsipeptides, or derivatives thereof, having the structure of formula (I), and uses thereof, e.g. as inhibitors of kallikrein 7 and human neutrophil elastase.Type: GrantFiled: August 18, 2008Date of Patent: May 15, 2012Assignee: Novartis AGInventors: Philipp Krastel, Brigitta-Maria Liechty, Josef Gottfried Meingassner, Esther Schmitt, Erwin Paul Schreiner
-
Publication number: 20120115783Abstract: The present invention provides novel peptidomimetic macrocycles and methods of using such macrocycles for the treatment of disease.Type: ApplicationFiled: September 22, 2009Publication date: May 10, 2012Applicant: Alleron therapeutics, IncInventors: Huw M. Nash, Rosana Kapeller-Libermann, Jiawen Han, Tomi K. Sawyer, Justin Noehre
-
Publication number: 20120115794Abstract: The present invention relates to the use of peptide compounds for the prevention and/or treatment of ophthalmic diseases. In particular, the present invention relates to a peptide compound comprising an amino acid sequence displayed by amino acids 7 to 11 of SEQ ID NO: 2 (KEQWFGNRWHEGYR) or of SEQ ID NO: 1 (KEKWFENEWQGKNP), or a functionally active derivative thereof, or a pharmaceutically acceptable salt thereof, for use in the prevention and/or treatmend of an ophthalmic disease in an individual. While SEQ ID NO: 2 is a part of the human CD44v6, SEQ ID NO: 1 is a part of the rat CD44v6.Type: ApplicationFiled: June 11, 2010Publication date: May 10, 2012Applicant: KARLSRUHER INSTITUT FÜR TECHNOLOGIEInventors: Alexandra Matzke, Helmut Ponta, Véronique Orian-Rousseau, Martina Tremmel
-
Publication number: 20120114557Abstract: Diagnostic compositions and methods for imaging and/or assessing collagen are described. The diagnostic compositions can include collagen binding peptides.Type: ApplicationFiled: September 12, 2011Publication date: May 10, 2012Applicant: COLLAGEN MEDICAL, LLCInventors: Peter D. Caravan, Andrew Kolodziej, Zhaoda Zhang, Stephane Dumas, Biplab Kumar Das, Vincent Jacques, Richard Looby, Steffi K. Koerner, Wei-Chuan Sun, David R. Buckler, Aida Abujoub, Aaron K. Sato
-
Publication number: 20120115793Abstract: The present invention provides novel peptidomimetic macrocycles and methods of using such macrocycles for the treatment of disease.Type: ApplicationFiled: September 22, 2009Publication date: May 10, 2012Applicant: Alleron Therapeutics, IncInventors: Huw M. Nash, Rosana Kapeller-Libermann, Jiawen Han, Tomi K. Sawyer, Justin Noehre